Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Annals of Hematology
|
January 7, 2011
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
Robert Chen, Joycelynne M Palmer, Leslie Popplewell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 23, 2011
High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors
Auayporn Nademanee, Joycelynne M Palmer, Leslie Popplewell, et al.
Molecular Cytogenetics
|
February 5, 2011
Evaluation of chronic lymphocytic leukemia by BAC-based microarray analysis
Roger A Schultz, Maria Delioukina, Karl Gaal, et al.
Leukemia & Lymphoma
|
June 25, 2011
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control
Jasmine Zain, Joycelynne M Palmer, Maria Delioukina, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 2, 2011
A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation
Mark H Kirschbaum, Anthony S Stein, Leslie Popplewell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2011
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
Mark Kirschbaum, Paul Frankel, Leslie Popplewell, et al.
Blood
|
July 24, 2019
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL
Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2025
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
September 6, 2022
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
Maria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, et al.
British Journal of Haematology
|
November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study
Ajai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Annals of Hematology
|
January 7, 2011
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
Robert Chen, Joycelynne M Palmer, Leslie Popplewell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 23, 2011
High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors
Auayporn Nademanee, Joycelynne M Palmer, Leslie Popplewell, et al.
Molecular Cytogenetics
|
February 5, 2011
Evaluation of chronic lymphocytic leukemia by BAC-based microarray analysis
Roger A Schultz, Maria Delioukina, Karl Gaal, et al.
Leukemia & Lymphoma
|
June 25, 2011
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control
Jasmine Zain, Joycelynne M Palmer, Maria Delioukina, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 2, 2011
A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation
Mark H Kirschbaum, Anthony S Stein, Leslie Popplewell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2011
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
Mark Kirschbaum, Paul Frankel, Leslie Popplewell, et al.
Blood
|
July 24, 2019
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL
Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2025
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
September 6, 2022
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
Maria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, et al.
British Journal of Haematology
|
November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study
Ajai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
Page
of 2